Bull, Bear & Beyond – SynAct Pharma: executive interview

In this interview, we speak with Jeppe Øvlesen, CEO, and Dr Thomas Jonassen, CSO of SynAct Pharma to discuss the company’s lead asset resomelagon, its unique mechanism of action and its broad applicability across inflammatory indications. Jeppe and Thomas also outline the ongoing Phase IIb trial, ADVANCE, evaluating resomelagon as a first-line treatment in rheumatoid arthritis in combination with the standard of care treatment methotrexate and SynAct’s plans for the asset. Jeppe and Thomas discuss the company’s operating performance and strong cash runway, providing headroom well past near-term catalysts, most importantly the ADVANCE trial top-line results, which are expected by end-Q126.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.